Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/μ-opioid receptor ligands: Implications for therapeutic applications

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 3, 2009, Pages 954-964

  Toll, Lawrence ^a   Khroyan, Taline V ^a   Polgar, Willma E ^a   Jiang, Faming ^a   Olsen, Cris ^a   Zaveri, Nurulain T ^a,b  

^a SRI INTERNATIONAL   (United States)

^b Astraea Therapeutics Inc   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 (2,3,3ALPHA,4,5,6 HEXAHYDRO 1H PHENALEN 1 YL)PIPERIDINL 4 YL)INDOLIN 2 ONE; 1 (1 CYCLOOCTYLPIPERIDIN 4 YL)INDOLIN 2 ONE); 3 ETHYL 1 (1 (4 ISOPROPYLCYCLOHEXYL)PIPERIDIN 4 YL)INDOLIN 2 ONE; ANTINOCICEPTIVE AGENT; MORPHINE; NALOXONE; NOCICEPTIN RECEPTOR; SR 14150; SR 16507; SR 16835; UNCLASSIFIED DRUG; LIGAND; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT; OPIATE RECEPTOR;

ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ABUSE; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; MOUSE; NONHUMAN; PAIN; PLACE PREFERENCE; PRIORITY JOURNAL; ANIMAL; ANIMAL BEHAVIOR; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL; COMPARATIVE STUDY; CONDITIONED REFLEX; CRICETULUS; DRUG EFFECT; DRUG POTENTIATION; GENETIC TRANSFECTION; HAMSTER; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; OPIATE ADDICTION; PROTEIN BINDING; PSYCHOLOGICAL ASPECT; RADIOASSAY; REWARD;

ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ANIMAL; CHO CELLS; CONDITIONING, CLASSICAL; CRICETINAE; CRICETULUS; HUMANS; LIGANDS; MALE; MICE; MICE, INBRED ICR; MOLECULAR STRUCTURE; OPIOID-RELATED DISORDERS; PAIN; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, OPIOID; RECEPTORS, OPIOID, MU; REWARD; TRANSFECTION;

EID: 73349112573     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.157446     Document Type: Article

References (41)

1. Bals-Kubik R, Herz A, and Shippenberg TS (1989) Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated. Psychopharmacology (Berl) 98:203-206.
2. Barlocco D, Cignarella G, Giuseppe G, Grugni M, and Ronzoni S (2004) inventors; Smithkline Beecham Corporation, assignee. Benzosuberonylpiperidine compounds as analgesics. U.S. patent 20040029917A1.
3. Bowen CA, Negus SS, Zong R, Neumeyer JL, Bidlack JM, and Mello NK (2003) Effects of mixed-action kappa/mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys. Neuropsychopharmacology 28:1125-1139.
4. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
5. Ciccocioppo R, Economidou D, Fedeli A, Angeletti S, Weiss F, Heilig M, and Massi M (2004) Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats. Psychopharmacology (Berl) 172:170-178.
6. Ciccocioppo R, Economidou D, Rimondini R, Sommer W, Massi M, and Heilig M (2007) Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. Biol Psychiatry 61:4-12.
7. Devine DP, Reinscheid RK, Monsma FJ Jr, Civelli O, and Akil H (1996) The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion. Brain Res 727:225-229.
8. Dooley CT, Spaeth CG, Berzetei-Gurske IP, Craymer K, Adapa ID, Brandt SR, Houghten RA, and Toll L (1997) Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. J Pharmacol Exp Ther 283:735-741.
9. Hasebe K, Kawai K, Suzuki T, Kawamura K, Tanaka T, Narita M, Nagase H, and Suzuki T (2004) Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence. Ann N Y Acad Sci 1025:404-413.
10. Higgins GA, Grottick AJ, Ballard TM, Richards JG, Messer J, Takeshima H, Pauly-Evers M, Jenck F, Adam G, and Wichmann J (2001) Influence of the selective ORL1 receptor agonist, Ro64-6198, on rodent neurological function. Neuropharmacology 41:97-107.
11. Hoskin PJ and Hanks GW (1991) Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs 41:326-344.
12. Huang P, Kehner GB, Cowan A, and Liu-Chen LY (2001) Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 297:688-695.
13. Khroyan TV, Zaveri NT, Polgar WE, Orduna J, Olsen C, Jiang F, and Toll L (2007) SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice. J Pharmacol Exp Ther 320:934-943.
14. Khroyan TV, Polgar WE, Jiang F, Zaveri NT, and Toll L (2009) Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/μ-opioid receptor agonists. J Pharmacol Exp Ther 331:946-953.
15. Ko MC, Woods JH, Fantegrossi WE, Galuska CM, Wichmann J, and Prinssen EP (2009) Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys. Neuropsychopharmacology 34:2088-2096.
16. Kotlinska J, Rafalski P, Biala G, Dylag T, Rolka K, and Silberring J (2003a) Nociceptin inhibits acquisition of amphetamine-induced place preference and sensitization to stereotypy in rats. Eur J Pharmacol 474:233-239.
17. Kotlinska J, Wichmann J, Rafalski P, Talarek S, Dylag T, and Silberring J (2003b) Non-peptidergic OP4 receptor agonist inhibits morphine antinociception but does not influence morphine dependence. Neuroreport 14:601-604.
18. Kuzmin A, Kreek MJ, Bakalkin G, and Liljequist S (2007) The nociceptin/orphanin FQ receptor agonist Ro 64-6198 reduces alcohol self-administration and prevents relapse-like alcohol drinking. Neuropsychopharmacology 32:902-910.
19. Kuzmin A, Sandin J, Terenius L, and Ogren SO (2003) Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of opioid receptor-like 1 receptor agonists and naloxone. J Pharmacol Exp Ther 304:310-318.
20. Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W, Kieffer BL, Takeshima H, Carroll FI, Maidment NT, et al. (2003) Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 23:10331-10337.
21. Marquez P, Baliram R, Kieffer BL, and Lutfy K (2007) The mu opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditioned place preference. Neuropharmacology 52:1336-1341.
22. Mello NK, Kamien JB, Lukas SE, Drieze J, and Mendelson JH (1993) The effects of nalbuphine and butorphanol treatment on cocaine and food self-administration by rhesus monkeys. Neuropsychopharmacology 8:45-55.
23. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butour JL, Guillemot JC, Ferrara P, and Monsarrat B (1995) Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377:532-535
24. Mogil JS, Grisel JE, Reinscheid RK, Civelli O, Belknap JK, and Grandy DK (1996a) Orphanin FQ is a functional anti-opioid peptide. Neuroscience 75:333-337.
25. Mogil JS, Grisel JE, Zhangs G, Belknap JK, and Grandy DK (1996b) Functional antagonism of mu-, delta- and kappa-opioid antinociception by orphanin FQ. Neurosci Lett 214:131-134.
26. Montoya ID, Gorelick DA, Preston KL, Schroeder JR, Umbricht A, Cheskin LJ, Lange WR, Contoreggi C, Johnson RE, and Fudala PJ (2004) Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther 75:34-48.
27. Murphy NP, Lee Y, and Maidment NT (1999) Orphanin FQ/nociceptin blocks acquisition of morphine place preference. Brain Res 832:168-170.
28. Neal CR Jr, Akil H, and Watson SJ Jr (2001) Expression of orphanin FQ and the opioid receptor-like (ORL1) receptor in the developing human and rat brain. J Chem Neuroanat 22:219-249.
29. Neal CR Jr, Mansour A, Reinscheid R, Nothacker HP, Civelli O, Akil H, and Watson SJ Jr (1999) Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding. J Comp Neurol 412:563-605.
30. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FJ Jr, and Civelli O (1995) Orphanin FQ: a neuropeptide that activates an opioid-like G protein-coupled receptor. Science 270:792-794.
31. Reiss D, Wichmann J, Tekeshima H, Kieffer BL, and Ouagazzal AM (2008) Effects of nociceptin/orphanin FQ receptor (NOP) agonist, Ro64-6198, on reactivity to acute pain in mice: comparison to morphine. Eur J Pharmacol 579:141-148.
32. Sakoori K and Murphy NP (2004) Central administration of nociceptin/orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice. Psychopharmacology (Berl) 172:129-136.
33. Shoblock JR, Wichmann J, and Maidment NT (2005) The effect of a systemically active ORL-1 agonist, Ro 64-6198, on the acquisition, expression, extinction, and reinstatement of morphine conditioned place preference. Neuropharmacology 49:439-446.
34. Spagnolo B, Calo G, Polgar WE, Jiang F, Olsen CM, Berzetei-Gurske I, Khroyan TV, Husbands SM, Lewis JW, Toll L, et al. (2008) Activities of mixed NOP and mu-opioid receptor ligands. Br J Pharmacol 153:609-619.
35. Suzuki T, Masukawa Y, Shiozaki Y, and Misawa M (1991) Potentiation of pentazocine conditioned place preference by tripelennamine in rats. Psychopharmacology (Berl) 105:9-12.
36. 35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol 47:848-854.
37. Tzschentke TM (2004) Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations. Psychopharmacology (Berl) 172:58-67.
38. Xu XJ, Hao JX, and Wiesenfeld-Hallin Z (1996) Nociceptin or antinociceptin: potent spinal antinociceptive effect of orphanin FQ/nociceptin in the rat. Neuroreport 7:2092-2094.
39. Yamamoto T, Nozaki-Taguchi N, and Kimura S (1997) Analgesic effect of intrathecally administered nociceptin, an opioid receptor-like1 receptor agonist, in the rat formalin test. Neuroscience 81:249-254.
40. Zaratin PF, Petrone G, Sbacchi M, Garnier M, Fossati C, Petrillo P, Ronzoni S, Giardina GA, and Scheideler MA (2004) Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111). J Pharmacol Exp Ther 308:454-461.
41. Zaveri NT, Jiang F, Olsen CM, Deschamps JR, Parrish D, Polgar W, and Toll L (2004) A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor. J Med Chem 47:2973-2976.